Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Unichem Laboratories Limited (506690) fair value: what the stock is really worth
We calculate from audited financials what Unichem Laboratories Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
UL
Broad data
Sep 13, 2026
Unichem Laboratories Limited
506690 · BSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹333.88 · Strongly overvalued (−38%)
!Quality 56/100
!Expensive Growth (revenue 5y +11.8 %/yr)
!Loss over the last twelve months · -1.6% net margin (TTM) · fiscal year 2025 6.5%
✓Low debt
·0.74% dividend yield
!Narrow moat 16/100
Watch Unichem Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹196.37 – ₹900.55 · fair‑value band ₹249.19 – ₹418.57 · the ₹537.45 price screens above the ₹333.88 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Company profile
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally.
Show more
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. It offers pharma products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients. The company was founded in 1944 and is based in Mumbai, India.
Stock analysis
Unichem Laboratories Limited (506690) currently trades at ₹537.45, while our model-based Fair Value estimate is ₹333.88, implying the stock looks roughly 61.0% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹359.37 per share, and 0 of the 17 models we run sit above the ₹537.45 price.
Bear case: the Earnings-Based group reads lowest at ₹184.78, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹249.19 (bear) to ₹418.57 (bull), the price of ₹537.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Unichem Laboratories Limited reported revenue of ₹21.1B in FY2025 versus ₹12.4B in FY2021, a compound +14.3%/yr. Reported net income was ₹1.4B in FY2025, compounding +41.5%/yr from FY2021.
Key figures
Market cap ₹17.3B (≈ $182M) · P/S ratio 1.32 · EPS (TTM) ₹−8.54 · Dividend yield 0.7% · Net margin 6.5% · Return on equity −0.8% · Return on assets (EBIT) −1.0% · Operating margin −3.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −38%, 506690 screens richer than that median.
Fair Value models
Bear ₹249.19
Fair Value ₹333.88
Bull ₹418.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income
₹269.62
₹273.75
₹269.55
76
Owner Earnings
₹210.62
₹359.37
₹603.34
74
EPV
₹165.92
₹194.39
₹219.30
74
All 17 models by family
DCF Models
Owner Earnings
₹210.62
₹359.37
₹603.34
74
Earnings-Based
Graham-Dodd
₹132.82
₹523.68
₹711.09
64
Lynch FV
₹129.34
₹184.78
₹240.21
61
PEG = 1.0
₹129.34
₹184.78
₹240.21
57
EPV
₹165.92
₹194.39
₹219.30
74
Dividend Discount
Gordon GGM
₹0.4400
₹0.9200
₹1.46
66
DDM Multi-Stage
₹0.4400
₹0.7800
₹0.9700
66
Multiples
P/E Multiple
₹322.29
₹429.71
₹537.14
63
P/S Multiple
₹249.04
₹332.05
₹415.07
58
P/B Multiple
₹249.04
₹332.05
₹415.07
55
EV/EBIT
₹249.19
₹333.88
₹418.57
66
EV/EBITDA
₹390.11
₹521.78
₹653.45
67
EV/Revenue
₹176.45
₹254.17
₹331.89
53
Asset-Based
NCAV (Graham)
₹174.03
₹233.20
₹348.07
54
Economic Profit
Residual Income
₹269.62
₹273.75
₹269.55
76
ROIC Compounder
₹165.92
₹194.39
₹219.30
72
Growth Earnings
Growth-Adj P/E
₹236.21
₹337.45
₹438.68
67
Notify me when 506690 reaches fair value
Put 506690 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
56/100
Of which business quality 55 · Market factors (momentum, volatility) 63
Profitability
40
Margins and returns on capital today
Quality Growth
78
Are margins and returns improving?
Cashflow
13
Earnings quality: real cash, not paper profit
Fin. Strength
60
Balance sheet, leverage, solvency risk
Investment
88
Disciplined investing over empire-building
Low Volatility
58
Calm price path (market factor)
Momentum
74
Price trend over the last 3–12 months (market factor)
52W Momentum
52
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.0%
Dividend (yield on the price)0.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11% → 7%
506690 screens 61% overvalued. Compare with Merck KGaA →
Compare Unichem Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Other · 128 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Other median · lower = cheaper
Context: sector, industry, market
- Is the Materials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €131.45 | €106.48 | −19% |
| Takeda Pharmaceutical Company TAK | $18.26 | $11.64 | −36% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥42.67 | ¥46.94 | +10% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,840 | ₹1,979 | +8% |
| Galderma Group GALD | CHF 154.95 | CHF 108.70 | −30% |
| Haleon plc HLN | $9.19 | $7.64 | −17% |
| Teva Pharmaceutical Industries Limited TEVA | $37.09 | $15.33 | −59% |
| Sandoz Group SDZ | CHF 66.74 | CHF 34.01 | −49% |
| Zoetis Inc ZTS | $72.97 | $104.88 | +44% |
| Hansoh Pharmaceutical Group 3692 | HK$32.72 | HK$35.99 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Unichem Laboratories Limited (506690) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹333.88 versus a price of ₹537.45, about −38% upside (overvalued).
What is the fair value of 506690?
Our model-based fair value for Unichem Laboratories Limited is ₹333.88 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹537.45.
What is the quality score of 506690?
Unichem Laboratories Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Unichem Laboratories Limited (506690)?
Our model-based price target is the fair value of ₹333.88 (as of Sep 13, 2026) from 17 valuation models. Cautious scenario ₹249.19, optimistic scenario ₹418.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Unichem Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹333.88, about −38% upside versus a price of ₹537.45 (overvalued). Cautious scenario ₹249.19, optimistic scenario ₹418.57. The calculation is refreshed regularly with new filings.
What is the revenue of Unichem Laboratories Limited (506690)?
Unichem Laboratories Limited reported trailing-twelve-month revenue of about ₹13.1B (latest available figure, as of Sep 13, 2026).
Does Unichem Laboratories Limited pay a dividend?
Unichem Laboratories Limited currently shows a dividend yield of about 0.74% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Unichem Laboratories Limited (506690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Unichem Laboratories Limited it is ₹333.88 per share (as of Sep 13, 2026), against a price of ₹537.45. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Unichem Laboratories Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 506690 trades above its calculated fair value: price ₹537.45, fair value ₹333.88, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 506690?
No. The price is what the market pays today (₹537.45); the fair value is what the company's own numbers justify (₹333.88). For Unichem Laboratories Limited the two are ₹203.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Unichem Laboratories Limited worth?
The market values Unichem Laboratories Limited at about ₹17.3B (market capitalisation, as of Sep 13, 2026). Per share that is ₹537.45; our models calculate a fair value of ₹333.88 per share.
What do the bullish and bearish scenarios say about 506690?
Our models span a range for Unichem Laboratories Limited: cautious scenario ₹249.19, base ₹333.88, optimistic ₹418.57 per share (as of Sep 13, 2026, price ₹537.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Unichem Laboratories Limited (506690)?
Balance-sheet figures for Unichem Laboratories Limited (as of Sep 13, 2026): return on equity −0.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 506690 from its 52-week high?
Unichem Laboratories Limited trades at ₹537.45, about 22% below its 52-week high of ₹685.95 and 92% above the low of ₹280.00 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹333.88 is for.
Which stocks are comparable to Unichem Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Unichem Laboratories Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹537.45, calculated fair value ₹333.88 (−38%), Quality Score 56/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 506690 calculated?
We run Unichem Laboratories Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹333.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Unichem Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Unichem Laboratories Limited right now?
The price sits above even our optimistic bull case (₹418.57). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Unichem Laboratories Limited
How large is the market capitalisation of Unichem Laboratories Limited (506690)?
The market capitalisation of Unichem Laboratories Limited is ₹17.3B (≈ $182M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Unichem Laboratories Limited (506690)?
The price-to-sales ratio of Unichem Laboratories Limited is 1.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Unichem Laboratories Limited (506690)?
Earnings per share at Unichem Laboratories Limited are ₹−8.54. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Unichem Laboratories Limited (506690)?
The dividend yield of Unichem Laboratories Limited is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Unichem Laboratories Limited (506690)?
The net margin of Unichem Laboratories Limited is 6.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Unichem Laboratories Limited (506690)?
The return on equity (ROE) of Unichem Laboratories Limited is −0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Unichem Laboratories Limited (506690)?
On an EBIT basis the return on assets of Unichem Laboratories Limited is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Unichem Laboratories Limited (506690)?
The operating margin of Unichem Laboratories Limited is −3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Unichem Laboratories Limited (506690)?
Revenue at Unichem Laboratories Limited is growing +7.4% versus a year earlier (3y avg +18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Unichem Laboratories Limited in the live analysis
One click puts Unichem Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.